Abstract

Mesenchymal stromal cells (MSCs) have been among the most intensively studied cells in recent years. Lack of specific unique markers for these cells makes it difficult to distinguish MSCs from other types of cells, such as fibroblasts or pericytes. MSCs are a mixture of morphologically different cells with expression of various cellular markers, with varying degrees of differentiation, as well as varying proliferation capacities. The majority of phenotypic features of these cells have been identified through cell culture. One of their basic features is the capacity to differentiate into three cell lines: osteoblasts, adipocytes and chondroblasts. Under in vivo conditions, MSCs form an important functional element of the hematopoietic stem cell niche. Residing within the blood vessel wall, MSCs assist in its formation and functioning. MSCs release anti‑apoptotic and pro‑angiogenic factors, as well as agents that stimulate cell proliferation and also immunostimulating factors.In this study, we focused in particular on therapeutic strategies employing MSCs to improve the performance of the infarcted heart as well as on their involvement in the repair of hard-to-heal wounds. Thanks to the released anti-inflammatory agents, MSCs can inhibit inflammatory reactions. Owing to cytokines and growth factors they can also stimulate regeneration of damaged tissues and organs. The therapeutic effect that follows MSCs administration is linked to their paracrine activity.

References

• 1. Armulik A., Genové G., Betsholtz C.: Pericytes: developmental,physiological, and pathological perspectives, problems, and promises.Dev. Cell, 2011; 21: 193-215
  Google Scholar
• 2. Baglio S.R., Pegtel D.M., Baldini N.: Mesenchymal stem cell secretedvesicles provide novel opportunities in (stem) cell-free therapy.Front. Physiol., 2012; 3: 359
  Google Scholar
• 3. Bajek A., Olkowska J., Drewa T.: Mezenchymalne komórki macierzystenarzędziem terapeutycznym w regeneracji tkanek i narządów.Postępy Hig. Med. Dośw., 2011; 65: 124-132
  Google Scholar
• 4. Bernardo M.E., Fibbe W.E.: Mesenchymal stromal cells: sensorsand switchers of inflammation. Cell Stem Cell, 2013; 13: 392-402
  Google Scholar
• 5. Bernardo M.E., Pagliara D., Locatelli F.: Mesenchymal stromalcell therapy: a revolution in Regenerative Medicine? Bone MarrowTransplant., 2012; 47: 164-171
  Google Scholar
• 6. Bianco P., Cao X., Frenette P.S., Mao J.J., Robey P.G., SimmonsP.J., Wang C.Y.: The meaning, the sense and the significance: translatingthe science of mesenchymal stem cells into medicine. Nat.Med., 2013; 19: 35-42
  Google Scholar
• 7. Blasi A., Martino C., Balducci L., Saldarelli M., Soleti A., NavoneS.E., Canzi L., Cristini S., Invernici G., Parati E.A., Alessandri G.: Dermalfibroblasts display similar phenotypic and differentiation capacityto fat-derived mesenchymal stem cells, but differ in anti-inflammatoryand angiogenic potential. Vasc. Cell, 2011; 3: 5
  Google Scholar
• 8. Braun J., Kurtz A., Barutcu N., Bodo J., Thiel A., Dong J.: Concertedregulation of CD34 and CD105 accompanies mesenchymal stromalcell derivation from human adventitial stromal cell. Stem Cells Dev.,2013; 22: 815-827
  Google Scholar
• 9. Bronckaers A., Hilkens P., Martens W., Gervois P., Ratajczak J.,Struys T., Lambrichts I.: Mesenchymal stem/stromal cells as a pharmacologicaland therapeutic approach to accelerate angiogenesis.Pharmacol. Ther., 2014; 143: 181-196
  Google Scholar
• 10. Caplan A.I.: All MSCs are pericytes? Cell Stem Cell, 2008; 3: 229230
  Google Scholar
• 11. Chen C.W., Okada M., Proto J.D., Gao X., Sekiya N., Beckman S.A.,Corselli M., Crisan M., Saparov A., Tobita K., Péault B., Huard J.: Humanpericytes for ischemic heart repair. Stem Cells, 2013; 31: 305-316
  Google Scholar
• 12. ClinicalTrials.gov. http://www.clinicaltrials.gov (04.04.2014)
  Google Scholar
• 13. Colter D.C., Sekiya I., Prockop D.J.: Identification of a subpopulationof rapidly self-renewing and multipotential adult stem cellsin colonies of human marrow stromal cells. Proc. Natl. Acad. Sci.USA, 2001; 98: 7841-7845
  Google Scholar
• 14. Corselli M., Chen C.W., Sun B., Yap S., Rubin J.P., Péault B.: Thetunica adventitia of human arteries and veins as a source of mesenchymalstem cells. Stem Cells Dev., 2012; 21: 1299-1308
  Google Scholar
• 15. Covas D.T., Panepucci R.A., Fontes A.M., Silva W.A. Jr., OrellanaM.D., Freitas M.C., Neder L., Santos A.R., Peres L.C., Jamur M.C., ZagoM.A.: Multipotent mesenchymal stromal cells obtained from diversehuman tissues share functional properties and gene-expressionprofile with CD146+ perivascular cells and fibroblasts. Exp. Hematol.,2008; 36: 642-654
  Google Scholar
• 16. Crisan M., Corselli M., Chen W.C., Péault B.: Perivascular cellsfor regenerative medicine. J. Cell. Mol. Med., 2012; 16: 2851-2860
  Google Scholar
• 17. Crisan M., Yap S., Casteilla L., Chen C.W., Corselli M., Park T.S.,Andriolo G., Sun B., Zheng B., Zhang L., Norotte C., Teng P.N., Traas J.,Schugar R., Deasy B.M., et all.: A perivascular origin for mesenchymalstem cells in multiple human organs. Cell Stem Cell, 2008; 3: 301-313
  Google Scholar
• 18. Dayan V., Yannarelli G., Billia F., Filomeno P., Wang X.H., DaviesJ.E., Keating A.: Mesenchymal stromal cells mediate a switch to alternativelyactivated monocytes/macrophages after acute myocardialinfarction. Basic Res. Cardiol., 2011; 106: 1299-1310
  Google Scholar
• 19. de Girolamo L., Lucarelli E., Alessandri G., Avanzini M.A., BernardoM.E., Biagi E., Brini A.T., D’Amico G., Fagioli F., Ferrero I., LocatelliF., Maccario R., Marazzi M., Parolini O., Pessina A., Torre M.L.,Italian Mesenchymal Stem Cell Group: Mesenchymal stem/stromalcells: a new ‚’cells as drugs’’ paradigm. Efficacy and critical aspectsin cell therapy. Curr. Pharm. Des., 2013; 19: 2459-2473
  Google Scholar
• 20. Ding L., Morrison S.J.: Haematopoietic stem cells and early lymphoidprogenitors occupy distinct bone marrow niches. Nature,2013; 495: 231-235
  Google Scholar
• 21. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., MariniF., Krause D., Deans R., Keating A., Prockop D.J., Horwitz E.: Minimalcriteria for defining multipotent mesenchymal stromal cells. TheInternational Society for Cellular Therapy position statement. Cytotherapy,2006; 8: 315-317
  Google Scholar
• 22. English K.: Mechanisms of mesenchymal stromal cell immunomodulation.Immunol. Cell Biol., 2013; 91: 19-26
  Google Scholar
• 23. Falanga V., Iwamoto S., Chartier M., Yufit T., Butmarc J., Kouttab N.,Shrayer D., Carson P.: Autologous bone marrow-derived cultured mesenchymalstem cells delivered in a fibrin spray accelerate healing inmurine and human cutaneous wounds. Tissue Eng., 2007; 13: 1299-1312
  Google Scholar
• 24. Frenette P.S., Pinho S., Lucas D., Scheiermann C.: Mesenchymalstem cell: keystone of the hematopoietic stem cell niche anda stepping-stone for regenerative medicine. Annu. Rev. Immunol.,2013; 31: 285-316
  Google Scholar
• 25. Friedenstein A.J., Chailakhjan R.K., Lalykina K.S.: The developmentof fibroblast colonies in monolayer cultures of guinea-pigbone marrow and spleen cells. Cell Tissue Kinet., 1970; 3: 393-403
  Google Scholar
• 26. Friedenstein A.J., Chailakhyan R.K., Latsinik N.V., Panasyuk A.F.,Keiliss-Borok I.V.: Stromal cells responsible for transferring the microenvironmentof the hemopoietic tissues. Cloning in vitro and retransplantationin vivo. Transplantation, 1974; 17: 331-340
  Google Scholar
• 27. Friedenstein A.J., Piatetzky-Shapiro I.I., Petrakova K.V.: Osteogenesisin transplants of bone marrow cells. J. Embryol. Exp. Morphol.,1966; 16: 381-390
  Google Scholar
• 28. Gaebel R., Furlani D., Sorg H., Polchow B., Frank J., Bieback K.,Wang W., Klopsch C., Ong L.L., Li W., Ma N., Steinhoff G.: Cell originof human mesenchymal stem cells determines a different healingperformance in cardiac regeneration. PLoS One, 2011; 6: e15652
  Google Scholar
• 29. Gnecchi M., Danieli P., Cervio E.: Mesenchymal stem cell therapyfor heart disease. Vascul. Pharmacol., 2012; 57: 48-55
  Google Scholar
• 30. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., MorelloF., Mu H., Melo L.G., Pratt R.E., Ingwall J.S., Dzau V.J.: Evidence supportingparacrine hypothesis for Akt-modified mesenchymal stemcell-mediated cardiac protection and functional improvement. FASEBJ., 2006; 20: 661-669
  Google Scholar
• 31. Greenbaum A., Hsu Y.M., Day R.B., Schuettpelz L.G., ChristopherM.J., Borgerding J.N., Nagasawa T., Link D.C.: CXCL12 in earlymesenchymal progenitors is required for haematopoietic stem-cellmaintenance. Nature, 2013; 495: 227-230
  Google Scholar
• 32. Haniffa M.A., Collin M.P., Buckley C.D., Dazzi F.: Mesenchymal stemcells: the fibroblasts’ new clothes? Haematologica, 2009; 94: 258-263
  Google Scholar
• 33. Hematti P.: Mesenchymal stromal cells and fibroblasts: a caseof mistaken identity? Cytotherapy, 2012; 14: 516-521
  Google Scholar
• 34. Ho A.D., Wagner W., Franke W.: Heterogeneity of mesenchymalstromal cell preparations. Cytotherapy, 2008; 10: 320-330
  Google Scholar
• 35. Horwitz E.M., Dominici M.: How do mesenchymal stromal cellsexert their therapeutic benefit? Cytotherapy, 2008; 10: 771-774
  Google Scholar
• 36. Horwitz E.M., Le Blanc K., Dominici M., Mueller I., Slaper-CortenbachI., Marini F.C., Deans R.J., Krause D.S., Keating A.: Clarificationof the nomenclature for MSC: The International Society forCellular Therapy position statement. Cytotherapy, 2005; 7: 393-395
  Google Scholar
• 37. Jackson W.M., Nesti L.J., Tuan R.S.: Concise review: clinical translationof wound healing therapies based on mesenchymal stem cells.Stem Cells Transl. Med., 2012; 1: 44-50
  Google Scholar
• 38. Jiang D., Qi Y., Walker N.G., Sindrilaru A., Hainzl A., Wlaschek M.,MacNeil S., Scharffetter-Kochanek K.: The effect of adipose tissuederived MSCs delivered by a chemically defined carrier on full-thicknesscutaneous wound healing. Biomaterials, 2013; 34: 2501-2515
  Google Scholar
• 39. Katare R., Riu F., Mitchell K., Gubernator M., Campagnolo P.,Cui Y., Fortunato O., Avolio E., Cesselli D., Beltrami A.P., AngeliniG., Emanueli C., Madeddu P.: Transplantation of human pericyteprogenitor cells improves the repair of infarcted heart through activationof an angiogenic program involving micro-RNA-132. Circ.Res., 2011; 109: 894-906
  Google Scholar
• 40. Kean T.J., Lin P., Caplan A.I., Dennis J.E.: MSCs: delivery routesand engraftment, cell-targeting strategies, and immune modulation.Stem Cells Int., 2013; 2013: 732742
  Google Scholar
• 41. Keating A.: Mesenchymal stromal cells: new directions. CellStem Cell, 2012; 10: 709-716
  Google Scholar
• 42. Korta K., Kupczyk P., Skóra J., Pupka A., Zejler P., Hołysz M., GajdaM., Nowakowska B., Barć P., Dorobisz A.T., Dawiskiba T., SzyberP., Bar J.: Stem and progenitor cells in biostructure of blood vesselwalls. Postępy Hig. Med. Dośw., 2013; 67: 982-995
  Google Scholar
• 43. Lai R.C., Chen T.S., Lim S.K.: Mesenchymal stem cell exosome:a novel stem cell-based therapy for cardiovascular disease. Regen.Med., 2011; 6: 481-492
  Google Scholar
• 44. Le Blanc K., Mougiakakos D.: Multipotent mesenchymal stromal cellsand the innate immune system. Nat. Rev. Immunol., 2012; 12: 383-396
  Google Scholar
• 45. Lee R.H., Pulin A.A., Seo M.J., Kota D.J., Ylostalo J., Larson B.L.,Semprun-Prieto L., Delafontaine P., Prockop D.J.: Intravenous hMSCsimprove myocardial infarction in mice because cells embolized inlung are activated to secrete the anti-inflammatory protein TSG-6.Cell Stem Cell, 2009; 5: 54-63
  Google Scholar
• 46. Leiker M., Suzuki G., Iyer V.S., Canty J.M. Jr., Lee T.: Assessmentof a nuclear affinity labeling method for tracking implanted mesenchymalstem cells. Cell Transplant., 2008; 17: 911-922
  Google Scholar
• 47. Li J., Ezzelarab M.B., Cooper D.K.: Do mesenchymal stem cellsfunction across species barriers? Relevance for xenotransplantation.Xenotransplantation, 2012; 19: 273-285
  Google Scholar
• 48. Lin C.S., Lue T.F.: Defining vascular stem cells. Stem Cells Dev.,2013; 22: 1018-1026
  Google Scholar
• 49. Lindner U., Kramer J., Rohwedel J., Schlenke P.: Mesenchymalstem or stromal cells: toward a better understanding of their biology?Transfus. Med. Hemother., 2010; 37: 75-83
  Google Scholar
• 50. Majesky M.W., Dong X.R., Hoglund V., Daum G., Mahoney W.M.Jr.: The adventitia: a progenitor cell niche for the vessel wall. CellsTissues Organs, 2012; 195: 73-81
  Google Scholar
• 51. Maxson S., Lopez E.A., Yoo D., Danilkovitch-Miagkova A., LerouxM.A.: Concise review: role of mesenchymal stem cells in wound repair.Stem Cells Transl. Med., 2012; 1: 142-149
  Google Scholar
• 52. Meirelles L. da S., Fontes A.M., Covas D.T., Caplan A.I.: Mechanismsinvolved in the therapeutic properties of mesenchymal stemcells. Cytokine Growth Factor Rev., 2009; 20: 419-427
  Google Scholar
• 53. Moll G., Rasmusson-Duprez I., von Bahr L., Connolly-AndersenA.M., Elgue G., Funke L., Hamad O.A., Lönnies H., Magnusson P.U.,Sanchez J., Teramura Y., Nilsson-Ekdahl K., Ringdén O., Korsgren O.,Nilsson B., Le Blanc K.: Are therapeutic human mesenchymal stromalcells compatible with human blood? Stem Cells, 2012; 30: 1565-1574
  Google Scholar
• 54. Murray I.R., West C.C., Hardy W.R., James A.W., Park T.S., NguyenA., Tawonsawatruk T., Lazzari L., Soo C., Péault B.: Natural history ofmesenchymal stem cells, from vessel walls to culture vessels. Cell.Mol. Life Sci., 2014; 71: 1353-1374
  Google Scholar
• 55. Owen M., Friedenstein A.J.: Stromal stem cells: marrow-derivedosteogenic precursors. Ciba Found. Symp., 1988; 136: 42-60
  Google Scholar
• 56. Pevsner-Fischer M., Levin S., Zipori D.: The origins of mesenchymalstromal cell heterogeneity. Stem Cell Rev., 2011; 7: 560-568
  Google Scholar
• 57. Phinney D.G., Sensebé L.: Mesenchymal stromal cells: misconceptionsand evolving concepts. Cytotherapy, 2013; 15: 140-145
  Google Scholar
• 58. Pojda Z., Machaj E., Kurzyk A., Mazur S., Dębski T., Gilewicz J.,Wysocki J.: Mezenchymalne komórki macierzyste. Postępy Biochem.,2013; 59: 187-197
  Google Scholar
• 59. Prockop D.J.: Concise review: two negative feedback loops placemesenchymal stem/stromal cells at the center of early regulatorsof inflammation. Stem Cells, 2013; 31: 2042-2046
  Google Scholar
• 60. Prockop D.J., Oh J.Y.: Mesenchymal stem/stromal cells (MSCs):role as guardians of inflammation. Mol. Ther., 2012; 20: 14-20
  Google Scholar
• 61. Rak J.: Extracellular vesicles – biomarkers and effectors of thecellular interactome in cancer. Front. Pharmacol., 2013; 4: Art. 21
  Google Scholar
• 62. Ranganath S.H., Levy O., Inamdar M.S., Karp J.M.: Harnessingthe mesenchymal stem cell secretome for the treatment of cardiovasculardisease. Cell Stem Cell, 2012; 10: 244-258
  Google Scholar
• 63. Rossini A., Frati C., Lagrasta C., Graiani G., Scopece A., Cavalli S.,Musso E., Baccarin M., Di Segni M., Fagnoni F., Germani A., Quaini E.,Mayr M., Xu Q., Barbuti A. i wsp.: Human cardiac and bone marrowstromal cells exhibit distinctive properties related to their origin.Cardiovasc. Res., 2011; 89: 650-660
  Google Scholar
• 64. Russell K.C., Phinney D.G., Lacey M.R., Barrilleaux B.L., MeyertholenK.E., O’Connor K.C.: In vitro high-capacity assay to quantifythe clonal heterogeneity in trilineage potential of mesenchymalstem cells reveals a complex hierarchy of lineage commitment. StemCells, 2010; 28: 788-798
  Google Scholar
• 65. Sacchetti B., Funari A., Michienzi S., Di Cesare S., Piersanti S.,Saggio I., Tagliafico E., Ferrari S., Robey P.G., Riminucci M., BiancoP.: Self-renewing osteoprogenitors in bone marrow sinusoids canorganize a hematopoietic microenvironment. Cell, 2007; 131: 324-336
  Google Scholar
• 66. Schofield R.: The relationship between the spleen colony-formingcell and the haemopoietic stem cell. Blood Cells, 1978; 4: 7-25
  Google Scholar
• 67. Sidney L.E., Branch M.J., Dunphy S.E., Dua H.S., Hopkinson A.:Concise review: evidence for CD34 as a common marker for diverseprogenitors. Stem Cells, 2014; 32: 1380-1389
  Google Scholar
• 68. Sorrell J.M., Caplan A.I.: Topical delivery of mesenchymal stemcells and their function in wounds. Stem Cell Res. Ther., 2010; 1: 30
  Google Scholar
• 69. Stoff A., Rivera A.A., Sanjib Banerjee N., Moore S.T., NumnumT.M., Espinosa-de-Los-Monteros A., Richter D.F., Siegal G.P., ChowL.T., Feldman D., Vasconez L.O., Mathis J.M., Stoff-Khalili M.A., CurielD.T.: Promotion of incisional wound repair by human mesenchymalstem cell transplantation. Exp. Dermatol., 2009; 18: 362-369
  Google Scholar
• 70. Tang J., Wang J., Guo L., Kong X., Yang J., Zheng F., Zhang L.,Huang Y.: Mesenchymal stem cells modified with stromal cell-derivedfactor 1 alpha improve cardiac remodeling via paracrine activationof hepatocyte growth factor in a rat model of myocardialinfarction. Mol. Cells, 2010; 29: 9-19
  Google Scholar
• 71. Traktuev D.O., Merfeld-Clauss S., Li J., Kolonin M., Arap W.,Pasqualini R., Johnstone B.H., March K.L.: A population of multipotentCD34-positive adipose stromal cells share pericyte and mesenchymalsurface markers, reside in a periendothelial location, andstabilize endothelial networks. Circ. Res., 2008; 102: 77-85
  Google Scholar
• 72. Uchibori R., Tsukahara T., Ohmine K., Ozawa K.: Cancer gene therapyusing mesenchymal stem cells. Int. J. Hematol., 2014; 99: 377-382
  Google Scholar
• 73. Wang J., Zhang S., Rabinovich B., Bidaut L., Soghomonyan S.,Alauddin M.M., Bankson J.A., Shpall E., Willerson J.T., Gelovani J.G.,Yeh E.T.: Human CD34+ cells in experimental myocardial infarction:long-term survival, sustained functional improvement, and mechanismof action. Circ. Res., 2010; 106: 1904-1911
  Google Scholar
• 74. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M.:A new mesenchymal stem cell (MSC) paradigm: polarization intoa pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype.PLoS One, 2010; 5: e10088
  Google Scholar
• 75. Watt S.M., Gullo F., van der Garde M., Markeson D., Camicia R.,Khoo C.P., Zwaginga J.J.: The angiogenic properties of mesenchymalstem/stromal cells and their therapeutic potential. Br. Med. Bull.,2013; 108: 25-53
  Google Scholar
• 76. Wuchter P., Boda-Heggemann J., Straub B.K., Grund C., KuhnC., Krause U., Seckinger A., Peitsch W.K., Spring H., Ho A.D., FrankeW.W.: Processus and recessus adhaerentes: giant adherens cell junctionsystems connect and attract human mesenchymal stem cells. CellTissue Res., 2007; 328: 499-514
  Google Scholar

Full text